NTRK1 and cancer: International expert consensus recommendations from the Japan Society of Clinical Oncology, European Society for Medical Oncology, ASCO, and the Taiwan Oncology Society strongly recommend the use of a TRK inhibitor during the course of therapy for any TRK fusion–positive cancer.